Identification

Name
Famotidine
Accession Number
DB00927  (APRD00296)
Type
Small Molecule
Groups
Approved
Description

A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [PubChem]

Structure
Thumb
Synonyms
  • (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
  • 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
  • 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
  • Famotidina
  • Famotidinum
  • N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
External IDs
L 643341 / MK-208 / YM-11170
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bci FamotidineTablet40 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bci FamotidineTablet20 mgOralBaker Cummins IncNot applicableNot applicableCanada
FamotidinePowder, for suspension40 mg/5mLOralPaddock Laboratories, Inc.2010-05-282017-10-26Us
Famotidine 10mgTablet10 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Famotidine InjectionSolution10 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Famotidine InjectionSolution10 mgIntravenousFresenius KabiNot applicableNot applicableCanada
Famotidine InjectionSolution10 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Famotidine InjectionSolution10 mgIntravenousHospira, Inc.Not applicableNot applicableCanada
Famotidine IV InjectionSolution10 mgIntravenousTevaNot applicableNot applicableCanada
Famotidine IV InjectionSolution10 mgIntravenousTevaNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-famotidine InjectableSolution10 mgIntravenousApotex Corporation2003-11-172013-08-02Canada
Apo-famotidine InjectableSolution10 mgIntravenousApotex Corporation2004-05-272013-08-02Canada
Apo-famotidine Tab 20mg USPTablet20 mgOralApotex Corporation1993-12-31Not applicableCanada
Apo-famotidine Tab 40mg USPTablet40 mgOralApotex Corporation1993-12-31Not applicableCanada
FamotidineTablet40 mg/1Oralbryant ranch prepack2016-01-292018-05-31Us
FamotidineTablet20 mg/1OralClinical Solutions Wholsesale2001-04-162017-11-02Us
FamotidineTablet40 mg/1OralDirectrx2017-10-30Not applicableUs
FamotidineTablet, film coated20 mg/1OralMc Kesson2001-04-16Not applicableUs
FamotidineTablet, film coated20 mg/1OralRemedy Repack2017-04-25Not applicableUs
FamotidineTablet20 mg/1OralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2009-07-012017-01-05Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Acid ControllerTablet20 mg/1Oral7 Eleven2014-08-05Not applicableUs
Acid ControlTablet20 mgOralApotex Corporation2014-04-28Not applicableCanada
Acid ControlTablet10 mgOralVita Health Products Inc1998-10-27Not applicableCanada
Acid ControlTablet10 mgOralPendopharm Division Of De Pharmascience Inc1997-09-082015-01-19Canada
Acid ControlTablet10 mgOralTeva1997-06-17Not applicableCanada
Acid ControlTablet10 mgOralApotex Corporation2000-07-11Not applicableCanada
Acid Control Original StrengthTablet10 mg/1OralMedicine Shoppe International2009-10-192017-11-30Us
Acid ControllerTablet20 mg/1OralShopko Stores Operating2013-07-17Not applicableUs
Acid ControllerTablet20 mg/1OralWalgreen2006-09-26Not applicableUs
Acid ControllerTablet20 mg/1OralH.E.B.2016-09-14Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acid Controller CompleteFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-052017-11-29Us
Acid Controller CompleteFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-052017-11-29Us
Acid Controller CompleteFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralSafeway2008-08-062017-12-22Us
Acid Controller Complete dual actionFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen2008-07-30Not applicableUs
Acid Controller Complete dual actionFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen2008-07-302018-03-29Us
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-06Not applicableUs
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralRite Aid2009-05-152018-04-01Us
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-12Not applicableUs
Acid Reducer CompleteFamotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FamotidineFamotidine (2 mg/mL)Injection, solutionIntravenousCantrell Drug Company2014-06-11Not applicableUs
International/Other Brands
Amfamox / Antodine / Confobos / Cronol / Digervin / Dispromil / Duovel / Durater / Famocid / Famosan / Famotep / Famox / Famoxal / Famtac / Famulcer / Fanosin / Fluxid / Gaster / Lecedil / Motiax / Mylanta AR / Notidin / Nulceran / Panalba / Pepcid / Pepcid RPD / Pepcidin / Pepcidine / Pepdine / Pepfamin / Quamatel / Renapepsa / Rubacina / Sedanium-R / Supertidine / Tairal / Tipodex / Ulfagel / Ulfamid / Ulgarine / Vagostal
Categories
UNII
5QZO15J2Z8
CAS number
76824-35-6
Weight
Average: 337.445
Monoisotopic: 337.044934829
Chemical Formula
C8H15N7O2S3
InChI Key
XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
IUPAC Name
3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide
SMILES
NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1

Pharmacology

Indication

For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).

Associated Conditions
Pharmacodynamics

Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.

Mechanism of action

Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.

TargetActionsOrganism
AHistamine H2 receptor
antagonist
Human
Absorption

The bioavailability of oral doses is 40-45%.

Volume of distribution
Not Available
Protein binding

15-20%

Metabolism

Hepatic.

Route of elimination

Renal clearance is 250-450 mL/min, indicating some tubular excretion.

Half life

2.5-3.5 hours

Clearance
  • renal cl=250-450 mL/min
Toxicity

Intravenous, mouse: LD50 = 244.4mg/kg; Oral, mouse: LD50 = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Famotidine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Famotidine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Famotidine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Famotidine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Famotidine.Experimental, Illicit
AbexinostatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Abexinostat.Investigational
AceprometazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Aceprometazine.Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Acrivastine.Approved
AgmatineThe serum concentration of Agmatine can be increased when it is combined with Famotidine.Experimental, Investigational
AlcaftadineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Alcaftadine.Approved
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Famotidine.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Alimemazine.Approved, Vet Approved
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Famotidine.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Amifampridine.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Amitriptyline.Approved
AmodiaquineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Famotidine.Approved
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Famotidine.Approved, Illicit, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Anagrelide.Approved
AntazolineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Antazoline.Approved
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Famotidine.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Aripiprazole lauroxil.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Astemizole.Approved, Withdrawn
AtazanavirFamotidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Famotidine.Approved
AzatadineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Azatadine.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Azithromycin.Approved
BedaquilineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Bedaquiline.Approved
BenzatropineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Benzatropine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Famotidine.Approved, Illicit
Benzylpenicilloyl PolylysineFamotidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Besifloxacin.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Famotidine.Approved, Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Bilastine.Approved, Investigational
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Famotidine.Approved, Investigational
BosutinibFamotidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BrompheniramineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Brompheniramine.Approved
BuclizineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Buclizine.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Buserelin.Approved, Investigational
ButriptylineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Butriptyline.Approved
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Carbinoxamine.Approved
CefditorenFamotidine can cause a decrease in the absorption of Cefditoren resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CefpodoximeFamotidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeFamotidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CeritinibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ceritinib.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Cetirizine.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorcyclizine.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative and stimulatory activities of Famotidine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholineThe serum concentration of Choline can be increased when it is combined with Famotidine.Approved, Nutraceutical
Choline salicylateThe serum concentration of Choline salicylate can be increased when it is combined with Famotidine.Approved, Nutraceutical
CilostazolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Cilostazol.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Famotidine.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Cinnarizine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Famotidine.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Citalopram.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Clemastine.Approved, Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClozapineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Clozapine.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Cocaine.Approved, Illicit
CrizotinibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Famotidine is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when Famotidine is combined with CUDC-907.Investigational
CyclizineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Cyclizine.Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Cyproheptadine.Approved
CysteamineFamotidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DabrafenibFamotidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DasatinibFamotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Degarelix.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Delamanid.Approved, Investigational
DelavirdineFamotidine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesfluraneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Desflurane.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Desloratadine.Approved, Investigational
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dexbrompheniramine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dexchlorpheniramine maleate.Approved
DexmethylphenidateThe therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Famotidine.Approved, Investigational
DextroamphetamineDextroamphetamine may decrease the sedative and stimulatory activities of Famotidine.Approved, Illicit
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Famotidine.Approved, Illicit
DifloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Difloxacin.Vet Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Diphenhydramine.Approved, Investigational
DisopyramideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Disopyramide.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dolasetron.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Donepezil.Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Famotidine.Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dosulepin.Approved
DoxepinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Doxepin.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Doxylamine.Approved, Vet Approved
DronedaroneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Dronedarone.Approved
DroperidolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Droperidol.Approved, Vet Approved
EbastineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ebastine.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Eliglustat.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Emedastine.Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Enoxacin.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Entinostat.Investigational
EpinastineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Epinastine.Approved, Investigational
EpinephrineThe serum concentration of Epinephrine can be increased when it is combined with Famotidine.Approved, Vet Approved
EribulinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Eribulin.Approved, Investigational
ErlotinibFamotidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Escitalopram.Approved, Investigational
EstradiolThe excretion of Estradiol can be decreased when combined with Famotidine.Approved, Investigational, Vet Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Felbamate.Approved
Ferric ammonium citrateFamotidine can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseFamotidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationFamotidine can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideFamotidine can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideFamotidine can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateFamotidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric subsulfateFamotidine can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateFamotidine can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateFamotidine can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideFamotidine can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateFamotidine can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateFamotidine can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateFamotidine can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateFamotidine can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesFamotidine can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilFamotidine can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolFamotidine can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FexofenadineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Fingolimod.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Fleroxacin.Approved
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Famotidine.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Flumequine.Withdrawn
FluoxetineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Flupentixol.Approved, Investigational, Withdrawn
FormoterolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Formoterol.Approved, Investigational
FosamprenavirFamotidine can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Famotidine.Approved
FurosemideThe excretion of Famotidine can be decreased when combined with Furosemide.Approved, Vet Approved
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Gadobenic acid.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Famotidine.Approved
GarenoxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Gatifloxacin.Approved, Investigational
GefitinibFamotidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Gemifloxacin.Approved, Investigational
GepefrineGepefrine may decrease the sedative and stimulatory activities of Famotidine.Experimental
GivinostatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Givinostat.Investigational
GleptoferronFamotidine can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GoserelinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Goserelin.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Granisetron.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Grepafloxacin.Approved, Investigational, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Haloperidol.Approved
HistamineThe serum concentration of Histamine can be increased when it is combined with Famotidine.Approved, Investigational
HistrelinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Histrelin.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Famotidine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative and stimulatory activities of Famotidine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Hydroxychloroquine.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Famotidine.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Famotidine.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ibutilide.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Iloperidone.Approved
ImatinibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Imatinib.Approved
ImipramineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Imipramine.Approved
IndacaterolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Indacaterol.Approved
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Famotidine.Approved
IndinavirFamotidine can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative and stimulatory activities of Famotidine.Approved
IronFamotidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranFamotidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Famotidine can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateFamotidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Famotidine.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Famotidine.Approved, Investigational
ItraconazoleFamotidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ivabradine.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ivosidenib.Approved, Investigational
KetoconazoleFamotidine can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ketotifen.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Famotidine.Approved, Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Lapatinib.Approved, Investigational
LedipasvirFamotidine can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LenvatinibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Lenvatinib.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Leuprolide.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Levocetirizine.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Levomethadyl Acetate.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative and stimulatory activities of Famotidine.Approved, Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Lithium cation.Experimental
LomefloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Lomefloxacin.Approved, Investigational
LopinavirThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Loratadine.Approved, Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Lumefantrine.Approved
MacimorelinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Macimorelin.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Maprotiline.Approved, Investigational
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Famotidine.Approved, Investigational
MemantineThe serum concentration of Memantine can be increased when it is combined with Famotidine.Approved, Investigational
MephedroneMephedrone may decrease the sedative and stimulatory activities of Famotidine.Investigational
MephentermineMephentermine may decrease the sedative and stimulatory activities of Famotidine.Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Mepyramine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Mequitazine.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Famotidine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Mesoridazine.Approved, Investigational
MetforminThe serum concentration of Metformin can be increased when it is combined with Famotidine.Approved
MethadoneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Methadone.Approved
MethamphetamineMethamphetamine may decrease the sedative and stimulatory activities of Famotidine.Approved, Illicit
MethotrimeprazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Methotrimeprazine.Approved, Investigational
MethoxyphenamineMethoxyphenamine may decrease the sedative and stimulatory activities of Famotidine.Experimental
MethylphenidateThe therapeutic efficacy of Methylphenidate can be decreased when used in combination with Famotidine.Approved, Investigational
MetoclopramideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Metoclopramide.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Famotidine.Approved
MidomafetamineMidomafetamine may decrease the sedative and stimulatory activities of Famotidine.Experimental, Illicit, Investigational
MifepristoneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Mifepristone.Approved, Investigational
MirabegronThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Mirabegron.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Famotidine.Approved
MMDAMMDA may decrease the sedative and stimulatory activities of Famotidine.Experimental, Illicit
MocetinostatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Mocetinostat.Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Famotidine.Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Moxifloxacin.Approved, Investigational
NafamostatThe serum concentration of Nafamostat can be increased when it is combined with Famotidine.Approved, Investigational
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Nalidixic Acid.Approved, Investigational
NelfinavirFamotidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Nemonoxacin.Investigational
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Famotidine.Approved, Investigational
NilotinibFamotidine can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NitroprussideFamotidine can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NorepinephrineThe serum concentration of Norepinephrine can be increased when it is combined with Famotidine.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Norfloxacin.Approved
NortriptylineThe risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Famotidine.Approved
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Famotidine.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ofloxacin.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Famotidine.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Olopatadine.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ondansetron.Approved
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Orbifloxacin.Vet Approved
OrphenadrineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Orphenadrine.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Oxaliplatin.Approved, Investigational
OxatomideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Oxatomide.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Oxolinic acid.Experimental
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Famotidine.Approved, Vet Approved
PaliperidoneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Paliperidone.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Papaverine.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Famotidine.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pasireotide.Approved
PazopanibFamotidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pefloxacin.Approved
PentamidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pentamidine.Approved, Investigational
PerflubutaneFamotidine can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerflutrenThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Perflutren.Approved
PheniramineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pheniramine.Approved
PhenterminePhentermine may decrease the sedative and stimulatory activities of Famotidine.Approved, Illicit
PimozideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pimozide.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pipemidic acid.Experimental
Piromidic acidThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Piromidic acid.Experimental
PitolisantThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pitolisant.Approved, Investigational
PosaconazoleThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Posaconazole.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Pracinostat.Investigational
PramipexoleThe serum concentration of Pramipexole can be increased when it is combined with Famotidine.Approved, Investigational
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Famotidine.Approved
PrimaquineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Primaquine.Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Procainamide.Approved
PromazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Promethazine.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Propafenone.Approved
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Famotidine.Approved, Investigational, Vet Approved
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Famotidine.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Prulifloxacin.Investigational
Prussian blueFamotidine can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Famotidine.Approved
QuetiapineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Quetiapine.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Quinine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Famotidine.Approved
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Famotidine.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Famotidine.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ricolinostat.Investigational
RilpivirineFamotidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RisedronateFamotidine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
RisperidoneThe risk or severity of QTc prolongation can be increased when Risperidone is combined with Famotidine.Approved, Investigational
RitobegronRitobegron may decrease the sedative and stimulatory activities of Famotidine.Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Famotidine.Approved, Investigational
RomidepsinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Romidepsin.Approved, Investigational
RosoxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Rosoxacin.Approved, Investigational
RoxithromycinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Roxithromycin.Approved, Investigational, Withdrawn
RufloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Rufloxacin.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Rupatadine.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Salmeterol.Approved
SaquinavirFamotidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sarafloxacin.Vet Approved, Withdrawn
SertralineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sertraline.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sevoflurane.Approved, Vet Approved
SitafloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sitafloxacin.Experimental, Investigational
Sodium feredetateFamotidine can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SolifenacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Solifenacin.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Famotidine.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sotalol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sparfloxacin.Approved, Investigational
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulfamethoxazole.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sultopride.Experimental
SunitinibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sunitinib.Approved, Investigational
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Famotidine.Approved
TandutinibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Tandutinib.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Technetium Tc-99m ciprofloxacin.Investigational
TelavancinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Telavancin.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Temafloxacin.Withdrawn
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Famotidine.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Terfenadine.Approved, Withdrawn
TeriflunomideThe serum concentration of Famotidine can be increased when it is combined with Teriflunomide.Approved
TerlipressinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Tetrabenazine.Approved, Investigational
TetracyclineThe excretion of Famotidine can be decreased when combined with Tetracycline.Approved, Vet Approved
TetraethylammoniumThe serum concentration of Tetraethylammonium can be increased when it is combined with Famotidine.Experimental, Investigational
Tetraferric tricitrate decahydrateFamotidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Thiothixene.Approved
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Famotidine.Approved, Investigational
TolterodineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Tolterodine.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Toremifene.Approved, Investigational
TrazodoneThe risk or severity of QTc prolongation can be increased when Trazodone is combined with Famotidine.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Famotidine.Approved, Investigational
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Famotidine.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Trimipramine is combined with Famotidine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Triprolidine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Triptorelin.Approved, Vet Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TucidinostatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Tucidinostat.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Famotidine.Approved
VareniclineFamotidine may decrease the excretion rate of Varenicline which could result in a higher serum level.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Famotidine.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Vilanterol.Approved
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Famotidine.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Vorinostat.Approved, Investigational
ZidovudineThe excretion of Zidovudine can be decreased when combined with Famotidine.Approved
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ziprasidone.Approved
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Limit caffeine intake.
  • Take without regard to meals, food may slightly increase the product's bioavailability.

References

Synthesis Reference

Montserrat Ballester-Rodes, Francisco E. Palomo-Nicolau, Antonio L. Palomo-Coli, "Famotidine polymorphic forms and their preparation process." U.S. Patent US5021582, issued March, 1987.

US5021582
General References
Not Available
External Links
Human Metabolome Database
HMDB0001919
KEGG Drug
D00318
PubChem Compound
3325
PubChem Substance
46507397
ChemSpider
3208
BindingDB
50036754
ChEBI
4975
ChEMBL
CHEMBL902
Therapeutic Targets Database
DAP000341
PharmGKB
PA449586
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Famotidine
ATC Codes
A02BA03 — FamotidineA02BA53 — Famotidine, combinations
AHFS Codes
  • 56:28.12 — Histamine H2-antagonists
FDA label
Download (1.05 MB)
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers / Lupus / Psoriasis1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedBasic ScienceDrug-Drug Interaction (DDI)1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedHealth Services ResearchHealthy Volunteers1
1CompletedScreeningFibrosis1
1CompletedTreatmentBioavailability2
1CompletedTreatmentCancers / Colorectal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Melanoma / Thyroid Papillary Carcinoma1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
1CompletedTreatmentPsoriasis1
1RecruitingBasic ScienceHealthy Volunteers1
1RecruitingTreatmentDiseases of Oesophagus Stomach and Duodenum1
1, 2RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2CompletedTreatmentCerebrovascular Accident, Acute / Edema of the cerebrum1
2CompletedTreatmentDyskinesias1
2Not Yet RecruitingTreatmentPlasmodium Infections1
2Not Yet RecruitingTreatmentPulmonary Arterial Hypertension (PAH) / Right Heart Failure1
2RecruitingTreatmentHNSCC / HPV-Related Squamous Cell Carcinoma1
2RecruitingTreatmentPlasma Cell Myeloma1
2, 3CompletedTreatmentMalaria caused by Plasmodium falciparum1
2, 3CompletedTreatmentReflux, Gastroesophageal1
2, 3RecruitingTreatmentSchizophrenic Disorders1
3CompletedPreventionUlcers1
3CompletedTreatmentErosive Esophagitis(EE)1
3CompletedTreatmentPeptic Ulcer Bleeding / Upper Gastrointestinal Hemorrhage1
3CompletedTreatmentReflux, Gastroesophageal1
3Not Yet RecruitingTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma2
3Not Yet RecruitingTreatmentMalaria caused by Plasmodium falciparum1
4Active Not RecruitingPreventionPeptic Ulcers1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
4CompletedPreventionMarginal Ulcers1
4CompletedPreventionPeptic Ulcer/Erosions1
4CompletedPreventionUlcers1
4CompletedTreatmentHeartburn1
4CompletedTreatmentJuvenile Idiopathic Arthritis (JIA)1
4CompletedTreatmentSchizophrenic Disorders1
4RecruitingTreatmentRheumatoid Arthritis1
4Unknown StatusTreatmentAspirin / Indigestion1
Not AvailableActive Not RecruitingTreatmentMetastatic Melanoma1
Not AvailableCompletedNot AvailableAnemias / Iron Deficiency / Plasmodium Infections / Schistosomiasis Infection1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedTreatmentPlasmodium Infections1
Not AvailableRecruitingPreventionPeptic Ulcers2
Not AvailableRecruitingSupportive CareCancer, Breast / Prophylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingTreatmentMalignant Neoplasm of Stomach1
Not AvailableUnknown StatusNot AvailableParasitemia1

Pharmacoeconomics

Manufacturers
  • Lupin ltd
  • Navinta llc
  • Salix pharmaceuticals inc
  • Akorn strides llc
  • Apotex inc richmond hill
  • Apothecon inc div bristol myers squibb
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Ben venue laboratories inc
  • Claris lifesciences ltd
  • Abbott laboratories
  • Baxter healthcare internati0nal specialty therapies div
  • Merck research laboratories div merck co inc
  • L perrigo co
  • Schwarz pharma inc
  • Actavis elizabeth llc
  • Alembic ltd
  • Apotex inc
  • Carlsbad technology inc
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Perrigo co
  • Ranbaxy laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Wockhardt ltd
  • Wockhardt americas inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Akorn Inc.
  • Amerisource Health Services Corp.
  • APP Pharmaceuticals
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Carlsbad Technology Inc.
  • Chain Drug
  • Corepharma LLC
  • CVS Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Johnson & Johnson Healthcare
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Lupin Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Merck & Co.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Northstar Rx LLC
  • Nucare Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedium
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Salix Pharmaceuticals
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • Strides Arcolab Limited
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Walgreen Co.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
  • Yung Shin Pharmaceutical Industry Ltd.
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, chewableOral
Tablet, coatedOral
For suspensionOral40 mg/5mL
InjectionIntravenous10 mg/mL
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous2 mg/mL
Injection, solutionIntravenous20 mg/50mL
Powder, for solutionOral40 mg/5mL
Powder, for suspensionOral40 mg/5mL
TabletOral10 mg/1
TabletOral40 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coated, extended releaseOral10 mg/1
SolutionIntravenous10 mg
TabletOral20 mg/1
TabletOral10 mg
Tablet, chewableOral20 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral10 mg/1
TabletOral20 mg
TabletOral40 mg
Tablet, coatedOral10 mg/1
Prices
Unit descriptionCostUnit
Pepcid 30 40 mg tablet Bottle125.5USD bottle
Pepcid 40 mg/5ml Suspension 50ml Bottle123.88USD bottle
Pepcid 30 20 mg tablet Bottle64.13USD bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 710ml Bottle10.15USD bottle
Mylanta 200-200-20 mg/5ml Suspension 710ml Bottle9.23USD bottle
Mylanta 200-200-20 mg/5ml Suspension 355ml Bottle7.99USD bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 355ml Bottle7.99USD bottle
Famotidine 40 mg tablet3.43USD tablet
Pepcid 40 mg tablet3.02USD tablet
Famotidine powder2.74USD g
Famotidine 20 mg tablet1.76USD tablet
Pepcid 20 mg tablet1.6USD tablet
Apo-Famotidine 40 mg Tablet1.11USD tablet
Mylan-Famotidine 40 mg Tablet1.11USD tablet
Novo-Famotidine 40 mg Tablet1.11USD tablet
Nu-Famotidine 40 mg Tablet1.11USD tablet
Pepcid ac 10 mg tablet0.72USD tablet
Famotidine 40 mg/4 ml vial0.71USD ml
Famotidine 500 mg/50 ml vial0.71USD ml
Apo-Famotidine 20 mg Tablet0.62USD tablet
Mylan-Famotidine 20 mg Tablet0.62USD tablet
Novo-Famotidine 20 mg Tablet0.62USD tablet
Nu-Famotidine 20 mg Tablet0.62USD tablet
Pepcid ac 20 mg tablet0.58USD tablet
Famotidine-ns 20 mg/10 ml syrg0.54USD ml
Pepcid ac 10 mg gelcap0.48USD capsule
Pepcid complete tablet chew0.4USD tablet
Famotidine 20 mg/2 ml vial0.36USD ml
Famotidine 10 mg/ml vial0.28USD ml
CVS Pharmacy acid controller 20 mg tablet0.24USD tablet
CVS Pharmacy acid controller tablet0.24USD tablet
Acid reducer 20 mg tablet0.22USD tablet
Acid controller 10 mg tablet0.21USD tablet
Mylanta gas 125 mg tablet chew0.16USD tablet
Acid reducer 10 mg tablet0.15USD tablet
Famotidine 10 mg tablet0.15USD tablet
Famotidine 20 mg piggyback0.13USD ml
Mylanta gelcap0.12USD capsule
Mylanta ultimate-strength tablet0.07USD tablet
Mylanta ultra chew tablet0.06USD tablet
Pv acid reducer 10 mg tablet0.05USD tablet
Mylanta liq0.02USD ml
Mylanta supreme antacid liq0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5075114No1993-05-232010-05-23Us
CA2178277No2000-11-142016-06-05Canada
CA2052679No1997-12-022011-08-21Canada
US6221392No1998-04-092018-04-09Us
US6024981No1998-04-092018-04-09Us
US5854267Yes1996-06-292016-06-29Us
US6814978Yes2002-02-262022-02-26Us
US5989588Yes1998-03-302018-03-30Us
US8067451No2006-07-182026-07-18Us
US8501228No2006-07-182026-07-18Us
US8318202No2006-07-182026-07-18Us
US8449910No2006-07-182026-07-18Us
US8309127No2006-07-182026-07-18Us
US8067033No2006-07-182026-07-18Us
US5667794Yes1995-11-022015-11-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)163.5 °CPhysProp
water solubility1000 mg/L (at 20 °C)MERCK INDEX (1996)
logP-0.64ISLAM,MS & NARURKAR,MM (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.271 mg/mLALOGPS
logP-0.2ALOGPS
logP-2ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area175.83 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity80.46 m3·mol-1ChemAxon
Polarizability32.02 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.9382
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.5839
P-glycoprotein inhibitor INon-inhibitor0.9044
P-glycoprotein inhibitor IINon-inhibitor0.8701
Renal organic cation transporterNon-inhibitor0.6802
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9297
Ames testNon AMES toxic0.5827
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable0.9324
Rat acute toxicity1.9523 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8366
hERG inhibition (predictor II)Inhibitor0.6481
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-000i-0029000000-087ab7a1109f0568738d
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-0udi-0900000000-d8a9ef8fc58c0c705232
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-000i-0900000000-e245f325e8c6f31a5fd0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0005-0940000000-a2bd7381011d29592cea
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0a4i-0090000000-10306158f008021f19a5
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-0090000000-90a70a7303c968311864
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-001i-0090000000-ac0250ad61059e58f431
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0002-0090000000-235724a37e50732fdf94
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4r-0950000000-0c16a77af1ba782fa15a
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4r-0950000000-02af106b93d1423b1342
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at the positions 2 and 3.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Thiazoles
Direct Parent
2,4-disubstituted thiazoles
Alternative Parents
Organic sulfuric acids and derivatives / Heteroaromatic compounds / Guanidines / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Dialkylthioethers / Azacyclic compounds / Amidines / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
2,4-disubstituted 1,3-thiazole / Organic sulfuric acid or derivatives / Heteroaromatic compound / Guanidine / Amidine / Azacycle / Dialkylthioether / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Sulfenyl compound
show 9 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, guanidines, 1,3-thiazole (CHEBI:4975)

Targets

Details
1. Histamine H2 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Fukuda M, Tanaka S, Suzuki S, Kusama K, Kaneko T, Sakashita H: Cimetidine induces apoptosis of human salivary gland tumor cells. Oncol Rep. 2007 Mar;17(3):673-8. [PubMed:17273750]
  3. Takahashi HK, Watanabe T, Yokoyama A, Iwagaki H, Yoshino T, Tanaka N, Nishibori M: Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. Epub 2006 May 24. [PubMed:16723495]
  4. Kesiova M, Alexandrova A, Yordanova N, Kirkova M, Todorov S: Effects of diphenhydramine and famotidine on lipid peroxidation and activities of antioxidant enzymes in different rat tissues. Pharmacol Rep. 2006 Mar-Apr;58(2):221-8. [PubMed:16702624]
  5. Lesclous P, Schramm F, Gallina S, Baroukh B, Guez D, Saffar JL: Histamine mediates osteoclastic resorption only during the acute phase of bone loss in ovariectomized rats. Exp Physiol. 2006 May;91(3):561-70. Epub 2006 Mar 2. [PubMed:16513821]
  6. Amagase K, Okabe S: On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion. J Pharmacol Sci. 2003 Jun;92(2):124-36. [PubMed:12832840]
  7. Weydert JA, Ball TM, Davis MF: Systematic review of treatments for recurrent abdominal pain. Pediatrics. 2003 Jan;111(1):e1-11. [PubMed:12509588]
  8. Miyata K, Kamato T, Nishida A, Honda K: Studies on the mechanism for the gastric mucosal protection by famotidine in rats. Jpn J Pharmacol. 1991 Feb;55(2):211-22. [PubMed:2067140]
  9. Leurs R, Brozius MM, Smit MJ, Bast A, Timmerman H: Effects of histamine H1-, H2- and H3-receptor selective drugs on the mechanical activity of guinea-pig small and large intestine. Br J Pharmacol. 1991 Jan;102(1):179-85. [PubMed:1646056]
  10. Inan A, Sen M, Surgit O, Ergin M, Bozer M: Effects of the histamine H2 receptor antagonist famotidine on the healing of colonic anastomosis in rats. Clinics (Sao Paulo). 2009;64(6):567-70. [PubMed:19578661]
  11. Ojiako K, Shingala H, Schorr C, Gerber DR: Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation. Am J Crit Care. 2008 Mar;17(2):142-7. [PubMed:18310651]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
  2. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
  3. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:32